(16797697), S. L., (16797700), S. D. P., (16797703), L. E. O., (16375918), E. G., (16797706), J. P. B., (15135437), D. W., . . . (14940894), T. J. P. (2025). Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
Citação do estilo Chicago (17ª ed.)(16797697), Stephanie Lheureux, et al. Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. 2025.
Citação MLA (9ª ed.)(16797697), Stephanie Lheureux, et al. Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. 2025.